152 Additional Definitions Clause Samples
152 Additional Definitions. Each of the following definitions is set forth in the Section of this Agreement indicated below: DEFINITION SECTION Additional Co-Development Budget 5.1(c) Additional Co-Development Option 5.5(a) Additional Co-Development Plan 5.1(c) Additional Co-Funding Termination Notice 5.5(f) Additional Co-Funding Termination Date 5.5(f) Additional JDC 3.2 Additional Option Period 5.5(b)(i) Additional Pivotal Period Costs 5.5(f) Agreement Preamble Alliance Manager 3.7 Arising Manufacturing Patent 8.2(b)(i) Arising Product-Specific Patent 8.2(b)(ii) Auditee 9.8(f) Audit Rights Holder 9.8(f)
152 Additional Definitions. Each of the following terms has the meaning described in the corresponding Section of this Agreement indicated below: 1L mTNBC Ph-II Trial 3.1.2 1L NSCLC All-Comers Trial 3.1.2 AAA 16.7.2(b) Accelerated Arbitration Expert 16.7.2(g) Acquiring Party 9.8.2(a) AdvanTIG-105 Study 3.1.3 AdvanTIG-205 Study 3.1.3 Additional CMO 7.3(d) Agreement Preamble Alliance Manager 2.8 Audited Party 8.5.2 Auditing Party 8.5.2 Auditor 8.5.2 BeiGene Preamble BeiGene Assumed Patent 10.2.4 BeiGene Indemnitees 14.1 BeiGene Clinical Trial Data 10.1.2 BeiGene Core Patent 10.3.1 BeiGene Permitted Commercialization Activities 5.1.2(a)(i) BeiGene U.S. Manufacturing Facility 7.3(b) Branding Strategy 5.2.1 CAPAs 7.3(c)(i) CIA 5.7 Chairpersons 2.7.1 Change of Control Notice 9.9 CMC 7.1 Co-Detailing Agreement 5.6(d) Competing Infringement 10.3.1 Competing Trademark Infringement 9.3.6(a) Competing Transaction 9.1.2(a) Copyright License 9.3.7 Cure Period 15.3.1 Data Processing Agreement 6.3 Data Review Period 3.1.9 Development Milestone Event 8.2.1(a) Development Milestone Payment 8.2.1(a) Disclosed Patent Agreement 8.3.4(a) Disclosed Patents 13.2(h) Disclosing Party 12.1 Disclosure Letter 13.4 Dispute 16.7.2(a) DOJ 11.1 Electronic Delivery 16.12 ESMO 1.116 Ex-U.S. Co-Detailing Right 5.6(c) Ex-U.S. Opt-In Date 5.6(c) Exclusive Product License 9.3.1 Execution Date Preamble Existing Regulatory Materials 4.2.1 Facility 7.3(c)(i) FTC 11.1 FTO Offset Remainder 8.3.5 Global Clinical Trial 3.2.4(a) HSR Filing Date 11.1 HSR Filing Notice 9.1.3 HSR Long-Stop Date 15.2.2 Indemnification Claim Notice 14.3.1 Indemnitee 14.3.1 Indemnitor 14.3.1 Insolvency Event 15.6.1 JCC 2.4 JDC 2.2 JIPC 2.6 JMAC 2.3 JPC 2.5 JSC 2.1.1 Joint Commercialization Committee or JCC 2.4 Joint Development Committee or JDC 2.1.3(c) Joint Medical Affairs Committee or JMAC 2.3 Joint Steering Committee or JSC 2.1.1 Loss of Marketing Exclusivity 8.3.3(b)(i) Manufacturing Know-How and Materials 7.4(a) Manufacturing Technology Transfer 7.4(a) Medical Journals 12.7.4 Meldeverfahren 8.4.2(c)(ii) Monotherapy Scientific Paper 12.7.6 Non-Exclusive Product License 9.3.2 Novartis Preamble Novartis Assumed Patent 10.2.2 Novartis Assumed Trademark 9.3.5(b) Novartis Controlled Patents 10.2.3 Novartis Indemnitees 14.2 Novartis-Initiated Trials 3.1.2 Novartis Manufacturing Know-How 15.7.2(c)(vii) Novartis Permitted Commercialization Activities 5.1.2(b) Novartis Study Design Agreement Notice 3.1.5(b) Novartis Trademarks 10.6 Option 9.1.1 Option Exe...